Korro Bio (KRRO) Stock Analysis & AI Equity Report
Korro Bio (KRRO) overview
Korro Bio (KRRO) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 6.4m and operating profit of USD -122m; the year-end share price was 8.01 USD and market capitalisation was USD 75.4m. Korro Bio is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Korro Bio's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Korro Bio
Korro Bio is a biopharmaceutical company developing genetic medicines based on RNA editing. Its approach uses engineered oligonucleotides to modify RNA and is intended to address rare and more prevalent diseases. The company’s programs include candidates designed to alter protein function through RNA editing, including a lead program focused on glutamine synthetase and a candidate targeting alpha-1 antitrypsin deficiency.
Generate the Korro Bio report
Korro Bio is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Korro Bio and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Korro Bio
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.